• Chromatin organisation and cancer prognosis: a pan-cancer study 

      Kleppe, Andreas; Albregtsen, Fritz; Vlatkovic, Ljiljana; Pradhan, Manohar; Nielsen, Birgitte; Hveem, Tarjei Sveinsgjerd; Askautrud, Hanne Arenberg; Kristensen, Gunnar S Balle; Nesbakken, Arild; Trovik, Jone; Wæhre, Haakon; Tomlinson, Ian; Shepherd, Neil A.; Novelli, Marco; Kerr, David J.; Danielsen, Håvard Emil (Peer reviewed; Journal article, 2018-03)
      Background: Chromatin organisation affects gene expression and regional mutation frequencies and contributes to carcinogenesis. Aberrant organisation of DNA has been correlated with cancer prognosis in analyses of the ...
    • The expressed mutational landscape of microsatellite stable colorectal cancers 

      Sveen, Anita; Johannessen, Bjarne; Eilertsen, Ina Andrassy; Røsok, Bård Ingvald; Gulla, Marie; Eide, Peter Andreas Wold; Bruun, Jarle; Kryeziu, Kushtrim; Meza, Leonardo Zepeda; Myklebost, Ola; Bjørnbeth, Bjørn Atle; Skotheim, Rolf I.; Nesbakken, Arild; Lothe, Ragnhild Adelheid (Journal article; Peer reviewed, 2021)
      Background Colorectal cancer is the 2nd leading cause of cancer-related deaths with few patients benefiting from biomarker-guided therapy. Mutation expression is essential for accurate interpretation of mutations as ...
    • Gene expression profiles of CMS2-epithelial/canonical colorectal cancers are largely driven by DNA copy number gains 

      Berg, Kaja Christine Graue; Sveen, Anita; Høland, Maren; Alagaratnam, Sharmini; Rasmussen, Marianne Berg; Danielsen, Stine Aske; Nesbakken, Arild; Søreide, Kjetil; Lothe, Ragnhild A (Peer reviewed; Journal article, 2019-07-15)
      About 80% of colorectal cancers (CRCs) have chromosomal instability, which is an integral part of aggressive malignancy development, but the importance of specific copy number aberrations (CNAs) in modulating gene expression, ...
    • Patient-reported outcomes in palliative gastrointestinal stenting: a Norwegian multicenter study 

      Larssen, Lene; Medhus, Asle W.; Hjermstad, Marianne J.; Kørner, Hartwig; Glomsaker, Tom Birger; Søberg, Taran; Gleditsch, Dagfinn; Hovde, Øistein; Nesbakken, Arild; Tholfsen, Jan K.; Skreden, Knut; Hauge, Truls (Peer reviewed; Journal article, 2011-04-13)
      Background The clinical effect of stent treatment has been evaluated by mainly physicians; only a limited number of prospective studies have used patient-reported outcomes for this purpose. The aim of this work was to study ...
    • Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy 

      Pedersen, Kjetil Boye; Jacob, Havjin; Frikstad, Kari-Anne; Nesland, Jahn M; Mælandsmo, Gunhild; Dahl, Olav; Nesbakken, Arild; Flatmark, Kjersti (Peer reviewed; Journal article, 2016-08)
      Current clinical algorithms are unable to precisely predict which colorectal cancer patients would benefit from adjuvant chemotherapy, and there is a need for novel biomarkers to improve the selection of patients. The ...
    • Simultaneous Resection of Primary Colorectal Cancer and Synchronous Liver Metastases: Contemporary Practice, Evidence and Knowledge Gaps 

      Kleive, Dyre; Aas, Eline; Angelsen, Jon-Helge; Bringeland, Erling Audun; Nesbakken, Arild; Nymo, Linn Såve; Schultz, Johannes Kurt; Søreide, Kjetil; Yaqub, Sheraz (Journal article; Peer reviewed, 2021)
      The timing of surgical resection of synchronous liver metastases from colorectal cancer has been debated for decades. Several strategies have been proposed, but high-level evidence remains scarce. Simultaneous resection ...
    • Survival and costs of colorectal cancer treatment and effects of changing treatment strategies: a model approach 

      Joranger, Pål; Nesbakken, Arild; Sorbye, Halfdan; Hoff, Geir; Oshaug, Arne; Aas, Eline (Peer reviewed; Journal article, 2020)
      New and emerging advances in colorectal cancer (CRC) treatment combined with limited healthcare resources highlight the need for detailed decision-analytic models to evaluate costs, survival and quality-adjusted life years. ...